Cystic Fibrosis (CF) Flow Rates Study

This study has been completed.
Information provided by:
Pharmaxis Identifier:
First received: October 23, 2008
Last updated: April 22, 2009
Last verified: April 2009

We wish to measure the inspiratory flow and volumes generated by the subjects inhaling from a spirometer with a high resistance dry powder inhaler in series in subjects with cystic fibrosis.

Cystic Fibrosis

Study Type: Observational
Study Design: Observational Model: Cohort
Official Title: An Open, Observational, Non-Interventional Study of Inspiratory Flow Rates and Volumes in Subjects With Cystic Fibrosis Inhaling Via a Spirometer With the High Resistance RS01 Dry Powder Inhaler Device in Series

Resource links provided by NLM:

Further study details as provided by Pharmaxis:

Primary Outcome Measures:
  • inspiratory flow rates [ Time Frame: single visit ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • inspiratory volumes [ Time Frame: single visit ] [ Designated as safety issue: No ]

Enrollment: 25
Study Start Date: January 2009
Study Completion Date: February 2009
Primary Completion Date: February 2009 (Final data collection date for primary outcome measure)
cystic fibrosis
adults and children with cystic fibrosis


Ages Eligible for Study:   6 Years to 50 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

CF 6yrs and above


Inclusion Criteria:

  • CF
  • FEV1 ≥ 30% and < 90% predicted

Exclusion Criteria:

  • Be considered "terminally ill" or listed for lung transplantation
  • Have had a lung transplant
  • Have had a significant episode of haemoptysis (>60 ml) in the three months prior to enrolment
  • Have had a myocardial infarction in the three months prior to enrolment
  • Have had a cerebral vascular accident in the three months prior to enrolment
  • Have had major ocular surgery in the three months prior to enrolment
  • Have had major abdominal, chest or brain surgery in the three months prior to enrolment
  • Have a known cerebral, aortic or abdominal aneurysm
  • Be breast feeding or pregnant
  • Be using beta blockers
  • Have unstable asthma
  Contacts and Locations
No Contacts or Locations Provided
  More Information

No publications provided

Responsible Party: Dr Brett Charlton, Pharmaxis Identifier: NCT00779077     History of Changes
Other Study ID Numbers: DPM-OSM-403
Study First Received: October 23, 2008
Last Updated: April 22, 2009
Health Authority: Australia: TGA

Keywords provided by Pharmaxis:
device characteristics

Additional relevant MeSH terms:
Cystic Fibrosis
Pancreatic Diseases
Digestive System Diseases
Lung Diseases
Respiratory Tract Diseases
Genetic Diseases, Inborn
Infant, Newborn, Diseases
Pathologic Processes processed this record on April 17, 2014